# [18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)

> **NCT01385033** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 20 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** [18F]MK-3328

## Key facts

- **NCT ID:** NCT01385033
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08-19
- **Primary completion:** 2012-05-15
- **Final completion:** 2012-05-15
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01385033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01385033, "[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01385033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*